Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab and Capmatinib Combination Therapy in Metastatic NSCLC
NCT05488314Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of amivantamab, capmatinib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Dec 2022; status: active, not recruiting.
02
Drugs
amivantamabcapmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05488314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488314.